ストックスクリーナーアプリを入手
0.0847
13.54%
0.0101
アフターアワーズ：
.08
-0.0047
-5.55%
前日終値:
$0.0746
開ける：
$0.0806
24時間の取引高:
135.59M
Relative Volume:
7.77
時価総額：
$3.76M
収益：
-
当期純損益:
$-53.12M
株価収益率:
-0.000778
EPS:
-108.8
ネットキャッシュフロー:
$-15.86M
1週間 パフォーマンス:
+17.64%
1か月 パフォーマンス:
+42.11%
6か月 パフォーマンス:
-93.33%
1年 パフォーマンス:
-98.50%
1日の値動き範囲:
$0.0761
$0.126
1週間の範囲:
$0.065
$0.1748
52週間の値動き範囲:
$0.0502
$21.40
Onconetix Inc Stock (ONCO) Company Profile
ONCO を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ONCO
Onconetix Inc
|
0.0847 | 3.19M | 0 | -53.12M | -15.86M | -108.80 |
|
ONC
Beigene Ltd Adr
|
228.38 | 25.07B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.65 | 109.14B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.27 | 36.39M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
594.32 | 56.98B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
71.31 | 5.39B | 0 | -153.72M | -103.81M | -2.00 |
Onconetix Inc (ONCO) 最新ニュース
Noram Receives Results for CVZ-66: High of 1540 ppm Intersection of 220ft (67.1 m) Averaging 1124 ppm of Lithium - The Globe and Mail
Correction: Onconetix Announces Financing Through a $2.0 Million Private Placement of Series C Preferred Stock and Warrants, Establishes a $25 Million Equity Line of Credit - Barchart.com
Onconetix, Inc. Announces Receipt of Additional Notice from Nasdaq - Bluefield Daily Telegraph
Critical Alert: Onconetix Hit With Second Nasdaq Delisting Notice as Deadline Looms - Stock Titan
Onconetix Inc [ONCO] Is Currently 14.45 above its 200 Period Moving Avg: What Does This Mean? - dbtnews.com
Onconetix Inc (ONCO) expanding its growth trajectory ahead - Sete News
ONCO Stock on the Rise: A Promising Investment - investchronicle.com
This morning’s top pick is Onconetix Inc (NASDAQ:ONCO) - uspostnews.com
Take off with Onconetix Inc (ONCO): Get ready for trading - Sete News
ONCO’s Stock Market Pendulum: Swinging Between Gains and Losses - investchronicle.com
Form 424B3Prospectus [Rule 424(b)(3)] - ADVFN
Form 8-KCurrent report - ADVFN
Onconetix faces third delisting threat since 2022 IPOCincinnati Business Courier - The Business Journals
Onconetix faces Nasdaq delisting over low share price By Investing.com - Investing.com India
Onconetix faces Nasdaq delisting over low share price - Investing.com
ONCO’s current quarter earnings: What analysts forecast? - uspostnews.com
ONCO stock plunges to 52-week low, touches $0.06 - Investing.com Australia
ONCO stock plunges to 52-week low, touches $0.06 By Investing.com - Investing.com South Africa
Cincinnati's Onconetix pursuing merger deal with drug development firm - The Business Journals
Onconetix Sets Stage For Potential Business Combination With Ocuvex Therapeutics - marketscreener.com
Onconetix eyes Ocuvex in potential merger to expand portfolio By Investing.com - Investing.com India
Onconetix, Ocuvex Therapeutics Sign Letter of Intent for Potential Merger; Shares Up Pre-Bell - marketscreener.com
Onconetix Inks Letter Of Intent For Potential Business Combination With Ocuvex - Nasdaq
Onconetix Signs Letter of Intent for Potential Business Combination with Ocuvex Therapeutics, Inc. - The Manila Times
Max Alderman, Partner at FE International, Recognized as a NACVA 2024 30 Under Thirty Honoree - The Manila Times
Onconetix eyes Ocuvex in potential merger to expand portfolio - Investing.com
Target Corp (TGT) Stock: 52-Week Performance Showcases Highs, Lows, and Trading Volume - investchronicle.com
Major Pipeline Expansion: Onconetix to Acquire FDA-Approved Eye Drug in Ocuvex Deal - Stock Titan
Another top executive departs Cincinnati public firm - WKRC
Onconetix executive chairman resigns in latest leadership exit; interim CFO named new top leader - The Business Journals
Onconetix Names Interim CFO Karina Fedasz as Interim CEO - MarketWatch
Onconetix Appoints Karina Fedasz as Interim CEO - TipRanks
Onconetix Delays Yearly Report Filing - TipRanks
Pre-market Movers: RGLS, SLNO, OCEA, OSRH... - RTTNews
Onconetix claims validation of prostate cancer test Proclarix in Danish cohort - Yahoo Finance
Onconetix Announces Successful Clinical Validation of its Innovative Prostate Cancer Test Proclarix in a Danish cohort - GlobeNewswire
Onconetix reveals Proclarix’s clinical performance at EAU congress - Investing.com India
Onconetix Announces Successful Clinical Validation Of Proclarix For Prostate Cancer In Danish Cohort - Nasdaq
Onconetix reveals Proclarix’s clinical performance at EAU congress By Investing.com - Investing.com South Africa
Onconetix Inc. Presents Promising Clinical Data for Proclarix® at 2025 EAU Congress - Nasdaq
Onconetix Inc (NASDAQ: ONCO): Blank Check On Growth? - Stocks Register
Onconetix Announces New Clinical Data for its Innovative - GlobeNewswire
Onconetix to Present Proclarix at EAU Congress 2025 - TipRanks
Onconetix, Inc. to Present Proclarix Study Results at 2025 EAU Congress in Madrid - Nasdaq
Groundbreaking 800-Patient Study Shows How Onconetix's Proclarix Test Prevents Unnecessary Prostate Biopsies - StockTitan
ONCO stock plunges to 52-week low, touches $0.12 By Investing.com - Investing.com Australia
ONCO stock plunges to 52-week low, touches $0.12 - Investing.com India
Onconetix taps industry veteran as executive chairman amid CEO resignation - The Business Journals
Onconetix names new executive chairman, appoints board member By Investing.com - Investing.com Australia
Onconetix names new executive chairman, appoints board member - Investing.com India
Onconetix Announces Leadership Changes and New Appointments - TipRanks
Onconetix Inc (ONCO) 財務データ
収益
当期純利益
現金流量
EPS
1.54%
7.58%
大文字化:
|
ボリューム (24 時間):